534: CH COVID-19: Office Hours - Other Considerations Regarding COVID-19 for RMD Patients

Hub Host(s)

• 

  Alfred Kim, MD, PhD

  Washington University School of Medicine
  St. Louis, MO, United States

  Disclosure(s): Alexion Pharmaceuticals: Consultant (Ongoing); AstraZeneca: Consultant (Ongoing); Aurinia Pharmaceuticals: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Exagen Diagnostics: Consultant (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Foghorn Therapeutics: Grant/Research Support (Ongoing); GlaxoSmithKline: Consultant (Ongoing), Grant/Research Support (Ongoing), Speaker/Honoraria (includes speakers bureau, symposia, and expert witness) (Ongoing); Kypha Inc.: Consultant (Ongoing), Intellectual Property/Patents (Ongoing); Pfizer: Consultant (Ongoing)

Community Speaker(s)

• YZ

  Yu (Ray) Zuo, MD, MS

  University of Michigan
  Ann Arbor, MI, United States

  Disclosure information not submitted.
• GS

  Grant Schulert, MD, PhD

  Cincinnati Children's Hospital Medical Center
  Cincinnati, OH, United States

  Disclosure(s): No financial relationships with ineligible companies to disclose
• 

  Leonard Calabrese, DO

  Board Certified Rheumatologist and the Head, Section of Clinical Immunology Department of Rheumatic & Immunologic Disease
  Cleveland Clinic
  Cleveland, OH, United States

  Disclosure information not submitted.